Role of MDM2 T309G Polymorphism in Susceptibility and Prognosis of Nonsmall Cell Lung Cancer: A Meta-Analysis

Abstract

This meta-analysis was performed to evaluate the relationships of a common polymorphism (T309G, rs2279744 T>G) in the murine double minute 2 (MDM2) gene with susceptibility and prognosis of nonsmall cell lung cancer (NSCLC). The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before November 1st, 2013 without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) or hazard risk (HR) with their 95% confidence intervals (95% CI) were calculated. Seven clinical studies with a total 3732 NSCLC patients and 1472 healthy controls met the inclusion criteria. The results of our meta-analysis suggested that MDM2 T309G polymorphism might be strongly correlated with an increased risk of NSCLC (G allele vs. T allele: OR=1.63, 95% CI: 1.42-1.89, p<0.001; TG+GG vs. TT: OR=1.54, 95% CI: 1.31-1.80, p<0.001; respectively). Furthermore, we observed significant associations of MDM2 T309G polymorphism with poor overall survival (TT vs. GT: HR=1.22, 95% CI: 101-1.43, p<0.001; TT vs. GG: HR=1.31, 95% CI: 1.04-1.59, p<0.001; TT vs. GT+GG: HR=1.44, 95% CI: 1.13-1.76, p<0.001; respectively) and progression-free survival (TT vs. GT+GG: HR=1.26, 95% CI: 0.82-1.69, p<0.001) of NSCLC patients. Our findings provide convincing evidence that the MDM2 T309G polymorphism may contribute to individual differences in NSCLC susceptibility and prognosis. Thus, the MDM2 T309G polymorphism may be a promising potential biomarker for NSCLC diagnosis and prognosis.